Key facts
- Thyme Care’s last known valuation is $1.5B (Sep 2025).
- It has raised $280.6M across 4 recorded rounds; the latest was Later Stage VC ($97.0M) in Apr 2025.
- Notable investors include Andreessen Horowitz, Bessemer Venture Partners, AlleyCorp, Foresite Capital, Wormhole Capital — 19 tracked in total.
- Thyme Care has filed 4 Form Ds with the SEC since 2021, most recently Sep 2025 ($97.0M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Thyme Care
Funding rounds
4 roundsAbout Thyme Care
Developer of an oncology care platform designed to guide cancer patients along their cancer journey. The company's platform offers physician-guided oncology nurses and resource specialists who provide education and guidance, generating actionable insights that allow doctors to identify at-risk members earlier and facilitate access to resources and care, enabling cancer patients to improve the cancer experience with early and ongoing intervention.
- Sector
- Healthcare
- HQ
- Nashville, TN, United States
- Founded
- 2020
- Employees
- 700
- Website
- thymecare.com/
- Ownership
- Privately Held (backing)
Thyme Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thyme Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thyme Care in its N-PORT filings yet. We sweep new filings monthly.